Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.35 | N/A | +221.95% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.35 | N/A | +221.95% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Sarepta Therapeutics reported a strong EPS performance, significantly exceeding expectations, which contributed to a slight increase in stock price. The lack of revenue figures and forward guidance may leave some investors cautious. Overall, the positive EPS surprise indicates potential confidence in the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DEXCOM INC
Aug 6, 2012